Recruiting NCT07733167
Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large Prostate: Exploring Its Role in Optimizing Surgical Outcomes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: TURP, Epinephrine.
- Who it may be relevant to
- Registry conditions: Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large Prostate. Basic parameters: from 40 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Intra-Prostatic Epinephrine injection in Bipolar Transurethral resection of large prostate: Exploring Its Role in Optimizing Surgical Outcomes
Interventions
- Device TURP
Intra-Prostatic Epinephrine injection in Bipolar Transurethral resection of large prostate - Drug Epinephrine
Intra-Prostatic epinephrine injection in Bipolar Transurethral resection of large prostate
Primary outcome measures
- Intraoperative blood loss , need of blood transfusion [Time frame: 24h post operative]
Secondary outcome measures (1)
- Prostate volume , post voiding residual urine [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Indication for Prostate Surgery or Procedure - Patients undergoing transurethral resection of the prostate (TURP)
- Prostate from 80 to 100 gm
- Failed medical therapy
Exclusion criteria
- Uncontrolled Hypertension - Patients with significantly high blood pressure despite medication therapy.
- Unstable angina, recent myocardial infarction, arrhythmias, or severe heart failure.
- Significant Coagulopathy - Patients with bleeding disorders or on anticoagulants where excessive vasoconstriction may lead to tissue necrosis or inadequate perfusion
- Hyperthyroidism, Pheochromocytoma or Endocrine Disorders - Patients with catecholamine-secreting tumors or other conditions that can lead to excessive sympathetic stimulation.
- Treatment in the last 3 months with 5-alpha reductase inhibitors.
- Genitourinary cancer, urinary tract lithiasis, and urological surgery within the last 3 months
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Ahmed Abdelraouf Saad — Banhā
Identifiers
NCT: NCT07733167 · ms 20-3-2025